We’ll help you create
innovative new products
We’re true partners with a proven
commercial record.
We’ll help you create
innovative new products
We’re true partners with a proven commercial record.
Creo’s founders have a history of successful innovation at scale.
The courage
to create
the future
Creo’s founders have a history of successful innovation at scale.
The courage to
create the future
Quality you can trust
By delivering pure cannabinoid ingredients in commercial quantities we’ll help you bring exciting new consumer products to the mass market.
A more sustainable source.
Available at scale.
High quality, consistent and free from contaminants.
Quality you can trust
By delivering pure cannabinoid ingredients in commercial quantities we’ll help you bring exciting new consumer products to the mass market.
A more sustainable source.
Available at scale.
High quality, consistent and free from contaminants.
Quality you can trust
By delivering pure cannabinoid ingredients in commercial quantities we’ll help you bring exciting new consumer products to the mass market.
A more sustainable source.
Available at scale.
High quality, consistent and free from contaminants.
CBG and CBGA
available at scale
CBG and CBGA
available at scale
CBG and CBGA offer enormous promise.
We’re enabling that promise to become reality.
CBG and CBGA
available at scale
CBG and CBGA offer enormous promise.
We’re enabling that promise to become reality.
A wide range of rare cannabinoids available now
You can now order a wide range of high-quality, rare cannabinoids
through our sourcing business, Curated by Creo.
Analyst firm Raymond James ranks Creo as one of the top players in the emerging cannabinoid biosynthesis market they estimate "growing from $10 bn in 2025 to $115 bn by 2040."
A wide range of rare cannabinoids available now
You can now order a wide range of high-quality, rare cannabinoids through our sourcing business, Curated by Creo.
Analyst firm Raymond James ranks Creo as one of the top players in the emerging cannabinoid biosynthesis market they estimate "growing from $10 bn in 2025 to $115 bn by 2040."
"Analyst firm Edison Research ranks Creo as one of the leadings players in the emerging cannabinoid biosynthesis market estimated to be worth some $30bn on an NPV basis.”